Skip to content

Sympathetic Nerve Activity Predictors in Patients With Chronic Obstructive Pulmonary Disease

Dissecting the Nature and Determinants of Sympathetic Nerve Activity in Patients With COPD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04849806
Acronym
SNAP-COPD
Enrollment
135
Registered
2021-04-19
Start date
2022-05-10
Completion date
2028-12-01
Last updated
2026-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catecholamine; Overproduction, COPD, Sympathetic Nervous System Diseases

Brief summary

The project will be pursued in our respiratory, autonomic nervous system physiology laboratory (Respiratory, autonomic nervous system physiology laboratory, Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital; Head of Department: Professor Michael Dreher). Overactivity of the sympathetic nerve activity (SNA) axis with "centrally" increased heart rate and peripheral vasoconstriction is a known phenomenon in patients with systolic heart failure (HF) and has recently been described in patients with primary lung disease as seen in chronic obstructive pulmonary disease (COPD). However, systematic analyses on this clinically relevant topic are currently lacking. Thus, using a comprehensive, multimodal approach and state-of-the-art technology, this research project is designed to determine the extent and nature of increased SNA in COPD (AIM 1) and evaluate the underlying mechanisms (AIM 2). The project will address the following hypotheses: 1. In COPD, concomitant obstructive sleep apnea is independently associated with increased SNA. 2. Precapillary pulmonary hypertension (PH), inspiratory muscle dysfunction and systemic inflammation describe a COPD phenotype characterised by increased SNA with a different subtype.

Detailed description

The project will be pursued in our respiratory, autonomic nervous system physiology laboratory (Respiratory, autonomic nervous system physiology laboratory, Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital; Head of Department: Professor Michael Dreher). Overactivity of the sympathetic nerve activity (SNA) axis is a known phenomenon in patients with systolic heart failure (HF) and has recently been described in patients with primary lung disease as seen in chronic obstructive pulmonary disease (COPD). Thus, insights into the nature of and factors involved in increased SNA in COPD are urgently needed. Potentially obstructive sleep apnea (OSA) with not only repetitive obstructions but also additional hypoxia and poor sleep quality additively increase SNA in COPD. In addition, inspiratory muscle dysfunction (if adequately measured by magnetic diaphragm stimulation studies and comprehensive diaphragm ultrasound) with related hypercapnia, pulmonary hypertension (PH) and systemic inflammation all likely also impact on SNA in COPD. However, systematic analyses on this clinically relevant topic are currently lacking. Thus, using a comprehensive, multimodal approach and state-of-the-art technology, this research project is designed to determine the extent and nature of increased SNA in COPD (AIM 1) and evaluate the underlying mechanisms (AIM 2). The project will address the following hypotheses: 1. In COPD, concomitant OSA with poor sleep is independently associated with increased SNA,. 2. PH, inspiratory muscle dysfunction and systemic inflammation describe a COPD phenotype characterised by increased SNA, manifesting differently. To test these hypotheses COPD patients without an established cardiovascular disease will be enrolled and the extent, nature and mechanism of SNA increase compared with healthy controls matched in a 3:1 ratio for age, sex and body mass index (BMI). Invasive assessment of muscle SNA to the point of single unit recordings with analysis of single postganglionic sympathetic firing, and hence SNA drive to the peripheral vasculature, is the gold standard for quantification of SNA in humans but is only available in a few centres worldwide because it is costly, time consuming and requires a high level of training. A small substudy will investigate the short term acute treatment effects of non-invasive ventilation and oxygen supplementation on SNA in patients with COPD.

Interventions

DIAGNOSTIC_TESTAssessments of the sympathetic nerve activity axis

For assessment sympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV . Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will also be assessed.

DIAGNOSTIC_TESTOSA severity

OSA is defined as apnoea-hypopnoea index \[AHI\] \>15/h and obstructive apnoea index \[OAI\] \>5/h) and sleep architecture

DIAGNOSTIC_TESTDetermination of PH and right HF severity

(defined as tricuspid annular plane systolic excursion ≤14 mm) and pulmonary arterial pressure (PAsys) using transthoracic echocardiography

DIAGNOSTIC_TESTComprehensive lung function and inspiratory muscle function testing.

Respiratory Muscle strength and function testing as previously established by our group and Assessment of daytime hypoxia (PaO2 \<55 mmHg) and hypercapnia (PaCO2 \>45 mmHg) using capillary blood gas analysis.

DIAGNOSTIC_TESTAssessment of systemic inflammation

Based on blood samples taken.

Sponsors

RWTH Aachen University
Lead SponsorOTHER
DFG - Deutsche Forschungs Gemeinschaft (German Research Foundation)
CollaboratorUNKNOWN

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 * Ability and willingness to give informed consent to participate in the study

Exclusion criteria

* Atrial fibrillation * Active pacing of the heart by a cardiac pacemaker (i.e. no intrinsic heart rate) * Clinically pre-established cardiovascular disease (e.g. arterial hypertension or systolic heart failure) * In-patient stay in the hospital within the last 4 weeks prior to the study examination date

Design outcomes

Primary

MeasureTime frameDescription
Assessments of the sympathetic nerve activity axis (Non invasive)2 yearssympathovagal balance (SVB), HRV and dBPV will be analysed using a 3-lead electrocardiogram (sampling rate 1000Hz) and a continuous non-invasive arterial blood pressure signal (CNAP® technology, sampling rate 100Hz). HRV (ms2 based on continuously recorded variability in RR intervals) and (diastolic) BPV (expressed as mmHg2 based on continuously recorded variability in diastolic BP) will be computed by time domain analysis and by frequency domain analysis and presented as the high frequency component (HF; 0.15-0.4 Hz), low frequency component (LF; 0.04-0.15 Hz), their relative ratio (LF/HF), and the very low frequency component (VLF; 0.0-0.04 Hz) for both HRV and dBPV .
Assessments of the sympathetic nerve activity axis (Invasive)2 yearsMuscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve Plasma catecholamines will be assessed Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve Plasma catecholamines will be assessed Muscle SNA will be recorded via a tungsten microelectrode carefully placed in the peroneal nerve. Plasma catecholamines will be assessed

Secondary

MeasureTime frameDescription
OSA severity2 yearsSee above
Determination of PH and right HF severity2 yearsSee above
Comprehensive lung function and inspiratory muscle function testing as previously described by our group2 yearsSee above
Assessment of systemic inflammation2 yearsSee above

Countries

Germany

Contacts

CONTACTMichael Dreher, Professor
mdreher@ukaachen.de+492418088763
CONTACTJens Dr. Spiesshoefer, MD
jspiesshoefe@ukaachen.de+492418037036
STUDY_DIRECTORMichael Dreher, Professor

RWTH Aachen University

PRINCIPAL_INVESTIGATORJens Spiesshoefer, MD

RWTH Aachen University

STUDY_CHAIRBinaya Regmi, MD

RWTH Aachen University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026